Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment.

Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment.

Item
http://www.wikidata.org/entity/Q36837364
Update on the treatment of type 2 diabetes mellitusGUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patientsOverview of Data Concerning the Safe Use of Antihyperglycemic Medications in Type 2 Diabetes Mellitus and Chronic Kidney Disease.Diabetes treatment in patients with renal disease: Is the landscape clear enough?Clinical review of glimepiride.Sulfonylurea treatment of type 2 diabetes mellitus: focus on glimepiride.The role of glimepiride in the treatment of type 2 diabetes mellitus.The role of self-monitoring of blood glucose in glucagon-like peptide-1-based treatment approaches: a European expert recommendation.Management of post-transplant diabetes.Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease.Detection of antidiabetic activity by crude paratoid gland secretions from common Indian toad (bufomelano stictus).Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide.Pharmacokinetics of rosiglitazone in patients with end-stage renal disease.Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia.Simultaneous Determination of Bosentan, Glimepiride, HYBOS and M1 in Rat Plasma by UPLC-MS-MS and its Application to Pharmacokinetic Study.Consensus Recommendations on Sulfonylurea and Sulfonylurea Combinations in the Management of Type 2 Diabetes Mellitus - International Task Force.Simultaneous determination of glimepiride and its metabolites in human plasma by liquid chromatography coupled to a tandem mass spectrometry.
P2860

Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment.

Item
http://www.wikidata.org/entity/Q36837364
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年論文
@yue
1996年論文
@zh-hant
1996年論文
@zh-hk
1996年論文
@zh-mo
1996年論文
@zh-tw
1996年论文
@wuu
1996年论文
@zh
1996年论文
@zh-cn
name
Pharmacokinetics and safety of ...... atients with renal impairment.
@en
type
label
Pharmacokinetics and safety of ...... atients with renal impairment.
@en
prefLabel
Pharmacokinetics and safety of ...... atients with renal impairment.
@en
P1433
P1476
P2093
P2888
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Pharmacokinetics and safety of ...... atients with renal impairment.
@en
P2093
P2888
P304
P31
P356
P433
P478
P577
P698